Does Fosamax Cause Osteonecrosis of the Jaw?

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Legacy Health Context and Transition to Occupational Exposure

Legacy health information resources have long provided the public with foundational knowledge on a wide range of medical topics, including the safe use of prescription medications. Within this general health context, discussions of bisphosphonate therapies such as Fosamax have historically focused on their primary indications for osteoporosis and bone density management. As these educational materials evolved, they began to acknowledge rare but serious adverse events, including osteonecrosis of the jaw, though typically in a clinical or patient-oriented framework. This general health perspective, however, does not fully address the distinct exposure patterns and risk factors encountered in occupational settings. In mass production environments, workers may handle raw materials, intermediates, or finished pharmaceutical products containing bisphosphonates, leading to potential inhalation or dermal contact over extended shifts. Unlike the controlled dosing in therapeutic use, occupational exposure can be chronic, intermittent, and unmonitored, raising distinct questions about causation and risk. The transition from general health information to occupational exposure concern requires careful consideration of how workplace conditions—such as inadequate ventilation, lack of personal protective equipment, or improper handling procedures—may modify the relationship between Fosamax exposure and osteonecrosis of the jaw. This pivot acknowledges that the legacy health context provides a necessary baseline, but the occupational lens demands a separate evaluation of exposure thresholds, duration, and cumulative effects that are not captured in patient-focused materials.

Bridging to Medical Evidence: Fosamax and ONJ Causation

Building on the legacy health context, it is essential to examine the medical evidence linking Fosamax (alendronate) to osteonecrosis of the jaw (ONJ). Fosamax is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). A recognized adverse effect associated with bisphosphonate therapy, including Fosamax, is osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed, non-healing bone in the maxillofacial region, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation of ONJ typically involves pain, swelling, infection, and exposed bone in the jaw, often following dental procedures. The causal relationship between Fosamax and ONJ is supported by multiple lines of evidence. The prescribing information for Fosamax explicitly states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This association is further corroborated by mechanistic studies that provide a multiscale characterization of jawbone, offering comprehensive information to help understand jawbone-specific responses to bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/).

Mechanisms and Risk Factors for Fosamax-Induced ONJ

The mechanistic pathways linking Fosamax to ONJ involve the drug's potent inhibition of osteoclast-mediated bone resorption, which can suppress normal bone turnover and remodeling. In the jawbone, which has a high rate of remodeling and is subject to frequent microtrauma from chewing and dental procedures, this suppression can impair the healing response. When combined with local factors such as infection, inflammation, or invasive dental procedures, the reduced bone turnover can lead to avascular necrosis and subsequent bone exposure. Risk factors for developing ONJ while taking Fosamax include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with the duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The timeline between exposure to Fosamax and the onset of ONJ symptoms can vary considerably. The time to onset of symptoms ranged from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This variability suggests that individual patient factors, such as dental health and concurrent medications, play a significant role in determining when ONJ manifests. In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), indicating that while ONJ is a known risk, its incidence in the general osteoporosis population may be low. However, for affected patients, the clinical interpretation is that Fosamax is a contributing factor, particularly when other risk factors are present.

Clinical Management and Safety Communication

From a safety-communication perspective, the prescribing information for Fosamax includes a specific warning about ONJ, advising that the drug should be discontinued if severe symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, although a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This pattern supports a causal role for Fosamax in triggering ONJ in susceptible individuals. For patients who develop ONJ, a comprehensive evaluation by a dental specialist is recommended, along with consideration of discontinuing bisphosphonate therapy, especially if invasive dental procedures are planned. In summary, the evidence indicates that Fosamax can cause osteonecrosis of the jaw, particularly in patients with additional risk factors such as dental procedures, cancer, or concomitant use of corticosteroids. The mechanism involves suppression of bone turnover in the jaw, leading to impaired healing and necrosis. The onset of symptoms can occur within days to months of starting the drug, and the risk increases with longer duration of use. Clinical management includes discontinuation of Fosamax if severe symptoms develop and careful dental monitoring for patients on long-term therapy.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified medical contexts for case-specific decisions.

Frequently Asked Questions

What is the link between Fosamax and osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate that can cause osteonecrosis of the jaw (ONJ) by suppressing bone turnover, impairing healing, and leading to avascular necrosis, especially when combined with risk factors like dental procedures or infection. The prescribing information explicitly reports ONJ in patients taking bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while on Fosamax?

Risk factors include invasive dental procedures, cancer, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders like periodontal disease or anemia. The risk increases with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How soon after starting Fosamax can ONJ symptoms appear?

The time to onset of ONJ symptoms can range from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Individual factors like dental health and concurrent medications influence this timeline.

Does submitting information create an medical context-client relationship?

No. Submission requests an initial records screening only and does not create an medical context-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.